Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 425.00% |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.28 Bn | 151.04 Mn | -124.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -124.56% |
| Dec 31, 2025 | 5,700.61% |
| Sep 30, 2025 | 404.84% |
| Jun 30, 2025 | 3,119.15% |
| Mar 31, 2025 | 48.74% |
| Dec 31, 2024 | 41.55% |
| Sep 30, 2024 | 141.44% |
| Jun 30, 2024 | 92.73% |
| Mar 31, 2024 | -12.99% |
| Dec 31, 2023 | 62.61% |
| Sep 30, 2023 | 38.67% |
| Jun 30, 2023 | 32.22% |
| Mar 31, 2023 | 38.93% |
| Dec 31, 2022 | 26.53% |
| Sep 30, 2022 | -39.39% |
| Jun 30, 2022 | -9.23% |
| Mar 31, 2022 | -27.52% |
| Dec 31, 2021 | 23.68% |
| Sep 30, 2021 | 39.16% |
| Jun 30, 2021 | 18.14% |